Use of cytokine immunotherapy to block CNS demyelination induced by a recombinant HSV-1 expressing IL-2

Gene Therapy

Volumn 18, Issue 7, 2011, Pages 734-742

  Zandian, M ^a   Mott, K R ^a   Allen, S J ^a   Dumitrascu, O ^a,b   Kuo, J Z ^b   Ghiasi, H ^a  

^a Regenerative Medicine Institute   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

IL 12; IL 35; multiple sclerosis; ocular; Recombinant virus

Indexed keywords

INTERLEUKIN 4; PLASMID DNA; RECOMBINANT CYTOKINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12P35; RECOMBINANT INTERLEUKIN 12P40; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 23; RECOMBINANT INTERLEUKIN 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DOSE RESPONSE; EYE INFECTION; FEMALE; HERPES SIMPLEX VIRUS 1; IMMUNOPATHOLOGY; IMMUNOTHERAPY; MIXED INFECTION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OPEN READING FRAME; OPTIC NERVE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; CENTRAL NERVOUS SYSTEM; CYTOKINES; DEMYELINATING DISEASES; FEMALE; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; IMMUNOTHERAPY; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

HUMAN HERPESVIRUS 1; MURINAE; MUS; SIMPLEXVIRUS;

EID: 79960141235     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.32     Document Type: Article

References (52)

1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153-187.
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
3. Hunter SF, Weinshenker BG, Carter JL, Noseworthy JH. Rational clinical immunotherapy for multiple sclerosis. Mayo Clin Proc 1997; 72: 765-780.
4. Soderstrom M, Ya-Ping J, Hillert J, Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998; 50: 708-714.
5. Sandberg-Wollheim M, Bynke H, Cronqvist S, Holtas S, Platz P, Ryder LP. A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 1990; 27: 386-393. (Pubitemid 20132053)
6. Rodriguez M, Siva A, Cross SA, O'Brien PC, Kurland LT. Optic neuritis: a populationbased study in Olmsted County, Minnesota. Neurology 1995; 45: 244-250.
7. O¢Riordan JI, Losseff NA, Phatouros C, Thompson AJ, Moseley IF, MacManus DG et al. Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination. J Neurol Neurosurg Psychiatry 1998; 64: 353-357. (Pubitemid 28159840)
8. Ghezzi A, Martinelli V, Torri V, Zaffaroni M, Rodegher M, Comi G et al. Long-term followup of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol 1999; 246: 770-775. (Pubitemid 29467151)
9. Lu CZ, Fredrikson S, Xiao BG, Link H. Interleukin-2 secreting cells in multiple sclerosis and controls. J Neurol Sci 1993; 120: 99-106. (Pubitemid 24011156)
10. Gallo P, Piccinno M, Pagni S, Tavolato B. Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 1988; 24: 795-797. (Pubitemid 19019036)
11. Gallo P, Piccinno MG, Pagni S, Argentiero V, Giometto B, Bozza F et al. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid. J Neurol Sci 1989; 92: 9-15. (Pubitemid 19217342)
12. Trotter JL, Clifford DB, McInnis JE, Griffeth RC, Bruns KA, Perlmutter MS et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol 1989; 25: 172-178. (Pubitemid 19051251)
13. Petitto JM, Streit WJ, Huang Z, Butfiloski E, Schiffenbauer J. Interleukin-2 gene deletion produces a robust reduction in susceptibility to experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci Lett 2000; 285: 66-70. (Pubitemid 30224625)
14. Ghiasi H, Osorio Y, Perng GC, Nesburn AB, Wechsler SL. Overexpression of interleukin- .2. by a recombinant herpes simplex virus type 1 attenuates pathogenicity and enhances antiviral immunity. J Virol 2002; 76: 9069-9078. (Pubitemid 34919865)
15. Ghiasi H, Osorio Y, Hedvat Y, Perng GC, Nesburn AB, Wechsler SL. Infection of BALB/c mice with a herpes simplex virus type 1 recombinant virus expressing IFN-g driven by the LAT promoter. Virology 2002; 302: 144-154. (Pubitemid 35356862)
16. Osorio Y, Sharifi BG, Perng G, Ghiasi NS, Ghiasi H. The role of T(H)1 and T(H)2 cytokines in HSV-1-induced corneal scarring. Ocul Immunol Inflamm 2002; 10: 105-116. (Pubitemid 36566893)
17. Ghiasi H, Osorio Y, Perng GC, Nesburn AB, Wechsler SL. Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice. J Virol 2001; 75: 9029-9036. (Pubitemid 32851907)
18. Parker JN, Pfister LA, Quenelle D, Gillespie GY, Markert JM, Kern ER et al. Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine 2006; 24: 1644-1652. (Pubitemid 43238241)
19. Osorio Y, La Point SF, Nusinowitz S, Hofman FM, Ghiasi H. CD8+-dependent CNS demyelination following ocular infection of mice with a recombinant HSV-1 expressing murine IL-2. Exp Neurol 2005; 193: 1-18. (Pubitemid 40463263)
20. Zandian M, Belisle R, Mott KR, Nusinowitz S, Hofman FM, Ghiasi H. Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2. Invest Ophthalmol Vis Sci 2009; 50: 3275-3282.
21. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O¢Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547-549. (Pubitemid 23161621)
22. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995; 154: 5071-5079.
23. Guler ML, Gorham JD, Hsieh CS, Mackey AJ, Steen RG, Dietrich WF et al. Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development. Science 1996; 271: 984-987.
24. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy KM. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci USA 1992; 89: 6065-6069.
25. Abehsira-Amar O, Gibert M, Joliy M, Theze J, Jankovic DL. IL-4 plays a dominant role in the differential development of Tho into Th1 and Th2 cells. J Immunol 1992; 148: 3820-3829.
26. Poliani PL, Brok H, Furlan R, Ruffini F, Bergami A, Desina G et al. Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum Gene Ther 2001; 12: 905-920. (Pubitemid 32681855)
27. Furlan R, Poliani PL, Marconi PC, Bergami A, Ruffini F, Adorini L et al. Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsingremitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther 2001; 8: 13-19. (Pubitemid 32162411)
28. Broberg E, Setala N, Roytta M, Salmi A, Eralinna JP, He B et al. Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Ther 2001; 8: 769-777. (Pubitemid 32509790)
29. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097-1102. (Pubitemid 17123439)
30. Osorio Y, Ghiasi H. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge. J Virol 2005; 79: 3297-3308. (Pubitemid 40327919)
31. Kahl KG, Kruse N, Toyka KV, Rieckmann P. Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis. J Neurol Sci 2002; 200: 53-55. (Pubitemid 34792742)
32. Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol 1995; 154: 450-458.
33. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J ExpMed 2001; 194: 669-676. (Pubitemid 32844776)
34. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387-1398.
35. Schwarz T. Interleukin-12 and its role in cutaneous sensitization. Res Immunol 1995; 146: 494-499. (Pubitemid 26054843)
36. Giri M, Ugen KE, Weiner DB. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 2004; 17: 370-389. (Pubitemid 38534033)
37. Koehler NK, Genain CP, Giesser B, Hauser SL. The human T cell response to myelin oligodendrocyte glycoprotein: a multiple sclerosis family-based study. J Immunol 2002; 168: 5920-5927. (Pubitemid 34556182)
38. Karp CL, van Boxel-Dezaire AH, Byrnes AA, Nagelkerken L. Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10? Curr Opin Neurol 2001; 14: 361-368. (Pubitemid 32510602)
39. Gran B, Zhang GX, Yu S, Li J, Chen XH, Ventura ES et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002; 169: 7104-7110. (Pubitemid 36899299)
40. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748. (Pubitemid 36227625)
41. Boulay JL, O'Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 2003; 19: 159-163. (Pubitemid 37011330)
42. Goriely S, Goldman M. Interleukin-12 family members and the balance between rejection and tolerance. Curr Opin Organ Transplant 2008; 13: 4-9.
43. Bancroft AJ, Humphreys NE, Worthington JJ, Yoshida H, Grencis RK. WSX-1: a key role in induction of chronic intestinal nematode infection. J Immunol 2004; 172: 7635-7641. (Pubitemid 38747628)
44. Miyazaki Y, Inoue H, Matsumura M, Matsumoto K, Nakano T, Tsuda M et al. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1- deficient mice. J Immunol 2005; 175: 2401-2407. (Pubitemid 41113850)
45. Wirtz S, Tubbe I, Galle PR, Schild HJ, Birkenbach M, Blumberg RS et al. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J Exp Med 2006; 203: 1875-1881. (Pubitemid 44188462)
46. Neufert C, Becker C, Wirtz S, Fantini MC, Weigmann B, Galle PR et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol 2007; 37: 1809-1816. (Pubitemid 47065120)
47. Yoshimoto T, Yasuda K, Mizuguchi J, Nakanishi K. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol 2007; 179: 4415-4423.
48. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007; 25: 221-242. (Pubitemid 46697908)
49. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569. (Pubitemid 350190247)
50. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007; 37: 3021-3029. (Pubitemid 350131282)
51. Ghiasi H, Wechsler SL, Kaiwar R, Nesburn AB, Hofman FM. Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1. J Virol 1995; 69: 334-340. (Pubitemid 24378810)
52. Osorio Y, Cohen J, Ghiasi H. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines. Invest Ophthalmol Vis Sci 2004; 45: 506-514. (Pubitemid 38140508)